Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche Set For Disruptive Entry To MS Market With 'Brave' Ocrevus Pricing Strategy

Executive Summary

Roche is taking no chances with its newly approved multiple sclerosis drug Ocrevus and has set a cost that ensures price is no barrier to treatment.

Advertisement

Related Content

Roche Seen Offering NICE Further Price Cut For MS Drug Ocrevus
Roche's Ocrevus: A Rare First-Year Blockbuster
A Deal For Biogen, But Not The One Investors Are Waiting For
A Year To Remember For US Drug Launches
EU Approval In Sight For New ATMP, Products For XLH And Diabetes, And 2nd Biosimilar Herceptin
Biogen Ventures Into Value-Based Contracts In Multiple Sclerosis
Tymlos Inclusion Stands Out As Express Scripts Reveals 2018 Formulary
As MS Space Awaits Ocrevus, MedDay Sees 'Synergistic' Positioning Opportunity
GeNeuro’s Causal Approach To MS Treatment Gathers Momentum
Phase III Endpoint Hit For Novartis's Gilenya Follow-On In Progressive MS

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC098478

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel